Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article discusses the newly approved drug dutasteride for managing benign prostatic hyperplasia, but reports no new research findings; the authors advise obtaining complete information before prescribing.

This review discusses various treatment options for lower urinary tract symptoms in men, including behavioral, pharmacologic, and surgical interventions, and reports no new clinical results; the authors emphasize first-line therapy with behavioral and pharmacologic approaches.

Finasteride may help reduce symptoms in male Tourette syndrome patients.

This study suggests that dutasteride may be more beneficial than finasteride for therapeutic or preventive use.

This study observed that new trienone compounds consistently showed higher 5alpha-reductase inhibitory activity compared to corresponding dienones across various biological models.

This article reviews the management of lower urinary tract symptoms, highlighting drug therapy advancements that have reduced the frequency of surgical interventions.

This review discusses hormonal control and treatment options for benign prostatic hyperplasia, highlighting similar efficacy and safety between finasteride and dutasteride, and reports no clinical results; further studies are suggested for new therapeutic agents.

This study concluded that alpha(1)-adrenoceptor antagonists are more effective than finasteride in the short term for reducing symptoms of lower urinary tract symptoms associated with benign prostatic hyperplasia.

This systematic review evaluated the efficacy and safety of dutasteride in men with benign prostatic hyperplasia and found that dutasteride significantly reduced the need for prostate surgery and acute urinary retention episodes compared to finasteride, with no significant difference in safety profiles between the two.

This study found that combining oral testosterone with dutasteride increased testosterone bioavailability in hypogonadal men while suppressing dihydrotestosterone levels over a 28-day period.

This article suggests that a topical sulfonylurea drug may inhibit excessive hair growth caused by diazoxide without affecting its beneficial effects on beta cells, potentially offering a treatment for various forms of hypertrichosis and hirsutism.

This research article focuses on nonsteroidal inhibitors of human type I steroid 5-alpha-reductase but reports no new results.

In this study, dutasteride treatment in retinitis pigmentosa mice increased photoreceptor survival and reduced glial activation, suggesting it may offer a neuroprotective effect.

Taking dutasteride every other day works as well as daily and better preserves sexual function.

This review provides a comprehensive overview of the mechanisms, efficacy, and adverse reactions of drugs commonly used for treating benign prostatic hyperplasia but reports no new clinical results.

In an animal study, researchers observed that a newly synthesized deoxycholic acid derivative showed similar prostate protection effects to finasteride in Wistar rats while being less toxic.

Dutasteride reduces DHT and improves BPH symptoms more effectively than finasteride.

This article discusses diabetic gustatory hyperhidrosis as a rare form of autonomic dysfunction linked to severe diabetic neuropathy and nephropathy, noting its impact on social and emotional well-being.

This study identified several drugs that may be potential candidates for repurposing as anti-hyperhidrosis treatments, based on their association with hypohidrosis or anhidrosis in the FDA Adverse Event Reporting System.

Dutasteride reduces DHT more effectively than finasteride.

This review discusses the pharmacologic effects, safety, and efficacy of dutasteride and finasteride for BPH, finding similar clinical benefits but greater DHT reduction with dutasteride and reports no new trial results.

This review examines the cognitive effects of medications for lower urinary tract symptoms and indicates that muscarinic antagonists, particularly oral oxybutynin, pose the highest risk for cognitive impairment.

This study found that Sonirid Duo, a combination of tamsulosin and finasteride, significantly improved symptoms and quality of life in patients with BPH over 12 months.

This study reports that dutasteride, used alone or with tamsulosin, effectively reduces acute urine retention and surgery risk in men with benign prostatic hyperplasia, and may lower prostate cancer incidence, suggesting potential chemopreventive benefits.

In this study, dual therapy with tamsulosin and solifenacin significantly improved urinary symptom severity and bladder capacity in BPH patients, but did not alter post-void residual urine volume. This supports using the combination therapy for managing LUTS, especially for storage-related symptoms, in clinical settings.